I made a post on 12/23/12 about a letter from MSKCC (number two rated cancer center in the country, who is also part of the NCCN, and has a Chair on the NCCN) to the Editor of The Journal of Clinical Oncology titled, "Should Cetuxmab Replace Cisplatin for Definitive Chemotherapy In Locally Advanced Head and Neck Cancer."

http://jco.ascopubs.org/content/early/2012/11/30/JCO.2012.46.9049

"..Howver, outide clinical trials, caution is substituting C225 for CDDP in patients positive for HPV, given recent data on from the metastic setting..."

"In conclusion, there is accumulating evidence from both prospective and retrospective studies that suggests that it may be premature to substitute EGFR inhibitors for cisplatin outside of a clinical trial. Until there is level I evidence from a randomized phase III noninferiority trial that demonstrates equivalence in outcomes between these two agents, we believe CDDP remains the preferred concurrent treatment. Fortunately, RTOG 10-16 is addressing thisquestion, although results will not be available for several years."

MSKCC reported their own centers retrospective experience with Cisplatin/RT vs Erbitux/RT and found Cisplatin/RT was superior in 2-year locoregional failure(5.7% vs 39.9%, failure free survival (87.4% vs 44.5%), and overall survival (92.8 vs 66.6%).

http://www.redjournal.org/article/S0360-3016(10)00930-2/abstract